Combined administration of human ghrelin and human growth hormone attenuates organ injury and improves survival in aged septic rats

Molecular Medicine

Volumn 22, Issue , 2016, Pages 124-135

  Yang, Weng Lang ^a,b   Ma, Gaifeng ^a   Zhou, Mian ^b   Aziz, Monowar ^b   Yen, Hao Ting ^a   Marvropoulos, Spyros A ^c   Ojamaa, Kaie ^b   Wang, Ping ^b  

^a TheraSource LLC   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CREATININE; GHRELIN; GROWTH HORMONE; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; LACTATE DEHYDROGENASE; LACTIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 2; MYELOPEROXIDASE; PROTEIN C FOS; TUMOR NECROSIS FACTOR;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; KIDNEY INJURY; LACTATE BLOOD LEVEL; LUNG INJURY; MALE; NONHUMAN; ORGAN INJURY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEPSIS; SURVIVAL RATE; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84987619508     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2015.00255     Document Type: Article

References (53)

1. Chang HJ, Lynm C, Glass RM. (2010) JAMA patient page. Sepsis. JAMA 304:1856.
2. Bosmann M, Ward PA. (2013) The inflammatory response in sepsis. Trends Immunol. 34:129-36.
3. Angus DC, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-10.
4. Martin GS, Mannino DM, Moss M. (2006) The effect of age on the development and outcome of adult sepsis. Crit. Care Med. 34:15-21.
5. Kojima M, et al. (1999) Ghrelin is a growth-hor-mone-releasing acylated peptide from stomach. Nature 402:656-60.
6. Takaya K, et al. (2000) Ghrelin strongly stimulates growth hormone release in humans. J. Clin. Endocrinol. Metab. 85:4908-11.
7. Arvat E, et al. (2001) Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J. Clin. Endocrinol. Metab. 86:1169-74.
8. Date Y, et al. (2000) Ghrelin, a novel growth hor-mone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255-61.
9. Gnanapavan S, et al. (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab. 87:2988.
10. Papotti M, et al. (2000) Growth hormone secretagogue binding sites in peripheral human tissues. J. Clin. Endocrinol. Metab. 85:3803-7.
11. Wang G, Lee HM, Englander E, Greeley GH, Jr. (2002) Ghrelin—not just another stomach hormone. Regul. Pept. 105:75-81.
12. Kojima M, Kangawa K. (2005) Ghrelin: structure and function. Physiol. Rev. 85:495-522.
13. Wu R, et al. (2005) Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc. Res. 68:318-26.
14. Wu R, et al. (2007) Ghrelin down-regulates proin-flammatory cytokines in sepsis through activation of the vagus nerve. Ann. Surg. 245:480-6.
15. Wu R, et al. (2007) Ghrelin attenuates sepsis-in-duced acute lung injury and mortality in rats. Am. J. Respir. Crit. Care Med. 176:805-13.
16. Wu R, et al. (2012) Ghrelin maintains the cardiovascular stability in severe sepsis. J. Surg. Res. 178:370-7.
17. Li B, et al. (2015) Ghrelin protects alveolar mac-rophages against lipopolysaccharide-induced apoptosis through growth hormone secretagogue receptor 1a-dependent c-Jun N-terminal kinase and Wnt/beta-catenin signaling and suppresses lung inflammation. Endocrinology 156:203-17.
18. Wei H, et al. (2015) Ghrelin inhibits proinflam-matory responses and prevents cognitive impairment in septic rats. Crit. Care Med. 43:e143-50.
19. Wu R, et al. (2009) Ghrelin hyporesponsiveness contributes to age-related hyperinflammation in septic shock. Ann. Surg. 250:126-33.
20. Sherlock M, Toogood AA. (2007) Aging and the growth hormone/insulin like growth factor-I axis. Pituitary 10:189-203.
21. Nass R, Park J, Thorner MO. (2007) Growth hormone supplementation in the elderly. Endocrinol. Metab. Clin. North Am. 36:233-45.
22. Heemskerk VH, Daemen MA, Buurman WA. (1999) Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev. 10:5-14.
23. Kolstad O, Jenssen TG, Ingebretsen OC, Vinnars E, Revhaug A. (2001) Combination of recombinant human growth hormone and glutamine-enriched total parenteral nutrition to surgical patients: effects on circulating amino acids. Clin. Nutr. 20:503-10.
24. Hattori N, et al. (2001) GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J. Clin. Endocrinol. Metab. 86:4284-91.
25. Deitch EA. (1998) Animal models of sepsis and shock: a review and lessons learned. Shock 9:1-11.
26. Yang J, et al. (2009) Human adrenomedullin and its binding protein attenuate organ injury and reduce mortality after hepatic ischemia-reperfusion. Ann. Surg. 249:310-7.
27. Idrovo JP, Yang WL, Nicastro J, Coppa GF, Wang P. (2012) Stimulation of carnitine palmi-toyltransferase 1 improves renal function and attenuates tissue damage after ischemia/reperfu-sion. J. Surg. Res. 177:157-64.
28. Andersen LW, et al. (2013) Etiology and therapeutic approach to elevated lactate levels. Mayo Clin. Proc. 88:1127-40.
29. Neumann B, et al. (1999) Mechanisms of acute inflammatory lung injury induced by abdominal sepsis. Int. Immunol. 11:217-27.
30. Nesseler N, et al. (2012) Clinical review: The liver in sepsis. Crit. Care 16:235.
31. Zarjou A, Agarwal A. (2011) Sepsis and acute kidney injury. J. Am. Soc. Nephrol. 22:999-1006.
32. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. (2009) Cell death. N. Engl. J. Med. 361:1570-83.
33. Wang P, Zhou M, Rana MW, Ba ZF, Chaudry IH. (1992) Differential alterations in microvascular perfusion in various organs during early and late sepsis. Am. J. Physiol. 263:G38-43.
34. Kawashima T, Okuno H, Bito H. (2014) A new era for functional labeling of neurons: activity-dependent promoters have come of age. Front. Neural Circuits 8:37.
35. Pierrakos C, Vincent JL. (2010) Sepsis biomark-ers: a review. Crit. Care 14:R15.
36. Suffredini AF, Munford RS. (2011) Novel therapies for septic shock over the past 4 decades. JAMA 306:194-9.
37. Jacob A, Wu R, Zhou M, Coppa GF, Wang P. (2010) Mechanism of the inhibitory effect of ghrelin in sepsis. Hepat. Med. 2:33-8.
38. Kobelt P, et al. (2008) Peripheral injection of ghrelin induces Fos expression in the dorso-medial hypothalamic nucleus in rats. Brain Res. 1204:77-86.
39. Wu R, et al. (2007) Ghrelin inhibits sympathetic nervous activity in sepsis. Am. J. Physiol. Endocrinol. Metab. 293:E1697-702.
40. van der Lely AJ, Tschop M, Heiman ML, Ghigo E. (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 25:426-57.
41. Albarran-Zeckler RG, Smith RG. (2013) The ghrelin receptors (GHS-R1a and GHS-R1b). Endocr. Dev. 25:5-15.
42. Garin MC, Burns CM, Kaul S, Cappola AR. (2013) Clinical review: The human experience with ghrelin administration. J. Clin. Endocrinol. Metab. 98:1826-37.
43. Adachi S, et al. (2010) Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology 138:1312-20.
44. Hiura Y, et al. (2012) Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients. Int. J. Clin. Oncol. 17:316-23.
45. Lundholm K, et al. (2010) Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 116:2044-52.
46. Rudman D, et al. (1990) Effects of human growth hormone in men over 60 years old. N. Engl. J. Med. 323:1-6.
47. Blackman MR, et al. (2002) Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288:2282-92.
48. Lange KH, et al. (2002) Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men. J. Clin. Endocrinol. Metab. 87:4966-75.
49. Liu H, et al. (2007) Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann. Intern. Med. 146:104-15.
50. Duska F, et al. (2008) Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation. Crit. Care Med. 36:1707-13.
51. Jeschke MG, et al. (2008) Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children. Pediatr. Crit. Care Med. 9:209-16.
52. Branski LK, et al. (2009) Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children. Ann. Surg. 250:514-23.
53. Takala J, et al. (1999) Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341:785-92.